Patient P-03086
Therapy response
Favorable
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
24%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S18
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Treatment adherence+9
- Toxicity+9
- GI instability+5
- Inflammatory activity-2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log4.8/10
improving · +0.4 vs previous 14 d
Stress level
Daily log4.6/10
stable · +0.1 vs previous 14 d
Pessimism score
Daily log3.2/10
improving · -0.2 vs previous 14 d
Sleep quality
Wearable37.3/100
stable · +1.1 vs previous 14 d
Libido
Daily log4.6/10
stable · +0.1 vs previous 14 d
HRV
Wearable48 ms
improving · +3.0 vs previous 14 d
Toxicity
Blood20.7/100
stable · -0.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 72 from the failing basin, 16 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -3.6 next day on high-intake days · n 18
Would not help
- Keep histamine lowGI +4.2 next day on high-intake days · n 20
- Keep alcohol lowGI +3.3 next day on high-intake days · n 21
- Keep caffeine lowGI +2.1 next day on high-intake days · n 14
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+4.2detractor · 95%
- Protein-3.6supporter · 95%
- Alcohol+3.3detractor · 95%
- Caffeine+2.1detractor · 65%
- Lactose+1.3no signal · 29%
- Dietary fat load-0.7no signal · 18%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓45
- WearableResting HR 79 bpm
- WearableShort sleep window
- Mucosal barrier integrity ↓40
- DNAFUT2 non-secretor lowers mucosal fucosylation
- WearableSleep 6.1 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 4.2 · butyrate capacity 48/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 53 ms
- Sleep
- 6.1 h
- Steps
- 7,946
- Resting HR
- 78 bpm
Daily log: GI score 30, nutritional resilience 61, adherence 97.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03105 | 47% | S12 | AD-05 | no change | 60 |
| P-03482 | 42% | S05 | AD-05 | no change | 67 |
| P-03187 | 37% | S12 | AD-05 | no change | 80 |
| P-03204 | 34% | S16 | AD-05 | improved | 48 |
| P-03351 | 32% | S07 | AD-05 | no change | 51 |
| P-03111 | 30% | S07 | AD-05 | no change | 48 |
| P-03208 | 41% | S02 | BR-03 | improved | 57 |
| P-03277 | 29% | S14 | BR-03 | improved | 41 |
| P-03308 | 29% | S04 | BR-03 | improved | 39 |
| P-03473 | 45% | S07 | DT-01 | improved | 70 |
| P-03213 | 38% | S02 | DT-01 | improved | 59 |
| P-03067 | 35% | S06 | DT-01 | no change | 50 |